Greece

Greece

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
1.8 (1.65 - 1.97) 2019 Modelled IHME
1.8 (1.65 - 1.96) 2018 Modelled IHME
1.81 (1.63 - 1.97) 2017 Modelled IHME
1.81 (1.64 - 1.97) 2016 Modelled IHME
1.81 (1.64 - 2) 2015 Modelled IHME
1.82 (1.65 - 2) 2014 Modelled IHME
1.83 (1.67 - 2.01) 2013 Modelled IHME
1.84 (1.68 - 2.02) 2012 Modelled IHME
1.86 (1.69 - 2.04) 2011 Modelled IHME
1.87 (1.71 - 2.06) 2010 Modelled IHME
1.89 (1.73 - 2.07) 2009 Modelled IHME
1.91 (1.75 - 2.09) 2008 Modelled IHME
1.93 (1.77 - 2.10) 2007 Modelled IHME
1.95 (1.77 - 2.13) 2006 Modelled IHME
1.97 (1.78 - 2.16) 2005 Modelled IHME
1.99 (1.81 - 2.18) 2004 Modelled IHME
2.01 (1.83 - 2.20) 2003 Modelled IHME
2.03 (1.85 - 2.21) 2002 Modelled IHME
2.04 (1.87 - 2.24) 2001 Modelled IHME
2.06 (1.88 - 2.27) 2000 Modelled IHME
2.08 (1.90 - 2.28) 1999 Modelled IHME
2.1 (1.92 - 2.30) 1998 Modelled IHME
2.12 (1.94 - 2.33) 1997 Modelled IHME
2.14 (1.95 - 2.35) 1996 Modelled IHME
2.15 (1.95 - 2.37) 1995 Modelled IHME
2.17 (1.97 - 2.38) 1994 Modelled IHME
2.18 (1.98 - 2.40) 1993 Modelled IHME
2.2 (2 - 2.42) 1992 Modelled IHME
2.21 (2.01 - 2.44) 1991 Modelled IHME
2.22 (2.01 - 2.47) 1990 Modelled IHME
3.3 (2.20 - 4.70) 2010 Modelled Drositis I et al, 2013
1.14 (0.91 - 1.46) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.05 (0.04 - 0.07) 2019 Modelled IHME
0.05 (0.04 - 0.07) 2018 Modelled IHME
0.05 (0.04 - 0.07) 2017 Modelled IHME
0.05 (0.04 - 0.07) 2016 Modelled IHME
0.05 (0.04 - 0.07) 2015 Modelled IHME
0.05 (0.04 - 0.07) 2014 Modelled IHME
0.05 (0.04 - 0.07) 2013 Modelled IHME
0.06 (0.04 - 0.07) 2012 Modelled IHME
0.06 (0.04 - 0.07) 2011 Modelled IHME
0.06 (0.04 - 0.08) 2010 Modelled IHME
0.06 (0.04 - 0.08) 2009 Modelled IHME
0.06 (0.05 - 0.08) 2008 Modelled IHME
0.07 (0.05 - 0.09) 2007 Modelled IHME
0.07 (0.05 - 0.09) 2006 Modelled IHME
0.07 (0.05 - 0.10) 2005 Modelled IHME
0.08 (0.06 - 0.10) 2004 Modelled IHME
0.08 (0.06 - 0.11) 2003 Modelled IHME
0.09 (0.07 - 0.12) 2002 Modelled IHME
0.1 (0.07 - 0.13) 2001 Modelled IHME
0.11 (0.09 - 0.14) 2000 Modelled IHME
0.18 (0.14 - 0.23) 1999 Modelled IHME
0.32 (0.25 - 0.42) 1998 Modelled IHME
0.49 (0.38 - 0.64) 1997 Modelled IHME
0.63 (0.49 - 0.82) 1996 Modelled IHME
0.71 (0.54 - 0.94) 1995 Modelled IHME
0.73 (0.55 - 0.96) 1994 Modelled IHME
0.75 (0.56 - 1) 1993 Modelled IHME
0.77 (0.57 - 1.02) 1992 Modelled IHME
0.78 (0.57 - 1.04) 1991 Modelled IHME
0.78 (0.57 - 1.05) 1990 Modelled IHME
0.37 (0.25 - 0.52) 2015 Modelled WHO
Showing out of
Show more
Pregnant women
Download
Value (%) Year Type Source
2.9 (2.40 - 3.50) 2003 Survey/reported Papaevangelou V et al, 2006

HBV-related death rate

National
Download
Value (per 100,000) Year Type Source
3.6 (2.89 - 4.48) 2019 Modelled IHME
3.59 (2.89 - 4.42) 2018 Modelled IHME
3.56 (2.87 - 4.40) 2017 Modelled IHME
3.55 (2.83 - 4.34) 2016 Modelled IHME
3.5 (2.79 - 4.29) 2015 Modelled IHME
3.5 (2.80 - 4.27) 2014 Modelled IHME
3.67 (2.98 - 4.45) 2013 Modelled IHME
3.65 (2.99 - 4.39) 2012 Modelled IHME
3.53 (2.90 - 4.25) 2011 Modelled IHME
3.37 (2.76 - 4.03) 2010 Modelled IHME
3.3 (2.70 - 3.93) 2009 Modelled IHME
3.25 (2.64 - 3.90) 2008 Modelled IHME
3.42 (2.80 - 4.13) 2007 Modelled IHME
3.37 (2.72 - 4.10) 2006 Modelled IHME
3.33 (2.68 - 4.07) 2005 Modelled IHME
3.23 (2.60 - 3.95) 2004 Modelled IHME
3.21 (2.58 - 3.91) 2003 Modelled IHME
3.17 (2.56 - 3.87) 2002 Modelled IHME
3.17 (2.54 - 3.89) 2001 Modelled IHME
3.18 (2.54 - 3.89) 2000 Modelled IHME
3.18 (2.55 - 3.91) 1999 Modelled IHME
3.14 (2.53 - 3.86) 1998 Modelled IHME
3.1 (2.48 - 3.82) 1997 Modelled IHME
3.11 (2.49 - 3.83) 1996 Modelled IHME
3.12 (2.50 - 3.85) 1995 Modelled IHME
3.13 (2.47 - 3.88) 1994 Modelled IHME
3.14 (2.48 - 3.91) 1993 Modelled IHME
3.17 (2.51 - 3.95) 1992 Modelled IHME
3.13 (2.47 - 3.91) 1991 Modelled IHME
3.11 (2.43 - 3.91) 1990 Modelled IHME
Showing out of
Show more
Technical notes

HBV-related deaths

National
Download
Value Year Type Source
372 (299 - 463) 2019 Modelled IHME
374 (300 - 460) 2018 Modelled IHME
373 (300 - 460) 2017 Modelled IHME
373 (297 - 457) 2016 Modelled IHME
370 (296 - 455) 2015 Modelled IHME
374 (299 - 457) 2014 Modelled IHME
396 (322 - 481) 2013 Modelled IHME
398 (326 - 479) 2012 Modelled IHME
389 (320 - 468) 2011 Modelled IHME
373 (306 - 447) 2010 Modelled IHME
366 (300 - 437) 2009 Modelled IHME
361 (294 - 434) 2008 Modelled IHME
381 (312 - 460) 2007 Modelled IHME
376 (303 - 457) 2006 Modelled IHME
372 (299 - 455) 2005 Modelled IHME
361 (290 - 440) 2004 Modelled IHME
358 (288 - 436) 2003 Modelled IHME
354 (286 - 432) 2002 Modelled IHME
353 (283 - 433) 2001 Modelled IHME
353 (281 - 432) 2000 Modelled IHME
352 (281 - 432) 1999 Modelled IHME
346 (278 - 425) 1998 Modelled IHME
338 (271 - 418) 1997 Modelled IHME
338 (270 - 416) 1996 Modelled IHME
337 (270 - 416) 1995 Modelled IHME
335 (265 - 416) 1994 Modelled IHME
335 (264 - 416) 1993 Modelled IHME
334 (265 - 417) 1992 Modelled IHME
327 (258 - 409) 1991 Modelled IHME
324 (253 - 406) 1990 Modelled IHME
967 2016 Modelled WHO
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
32 (24 - 42) 2019 Modelled IHME
32 (24 - 42) 2018 Modelled IHME
32 (24 - 42) 2017 Modelled IHME
32 (24 - 42) 2016 Modelled IHME
32 (24 - 42) 2015 Modelled IHME
32 (24 - 42) 2014 Modelled IHME
32 (24 - 43) 2013 Modelled IHME
32 (24 - 42) 2012 Modelled IHME
32 (24 - 42) 2011 Modelled IHME
32 (24 - 42) 2010 Modelled IHME
32 (24 - 42) 2009 Modelled IHME
32 (24 - 42) 2008 Modelled IHME
33 (24 - 43) 2007 Modelled IHME
34 (25 - 44) 2006 Modelled IHME
34 (25 - 44) 2005 Modelled IHME
34 (25 - 44) 2004 Modelled IHME
34 (25 - 44) 2003 Modelled IHME
34 (25 - 44) 2002 Modelled IHME
34 (25 - 44) 2001 Modelled IHME
34 (25 - 44) 2000 Modelled IHME
34 (25 - 44) 1999 Modelled IHME
34 (25 - 44) 1998 Modelled IHME
34 (25 - 44) 1997 Modelled IHME
34 (25 - 44) 1996 Modelled IHME
34 (25 - 44) 1995 Modelled IHME
34 (25 - 44) 1994 Modelled IHME
34 (25 - 43) 1993 Modelled IHME
34 (25 - 43) 1992 Modelled IHME
34 (25 - 43) 1991 Modelled IHME
34 (25 - 43) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
96 2018 Survey/reported WHO/UNICEF
96 2017 Survey/reported WHO/UNICEF
96 2016 Survey/reported WHO/UNICEF
96 2015 Survey/reported WHO/UNICEF
96 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
98 2012 Survey/reported WHO/UNICEF
95 2011 Survey/reported WHO/UNICEF
95 2010 Survey/reported WHO/UNICEF
95 2009 Survey/reported WHO/UNICEF
95 2008 Survey/reported WHO/UNICEF
95 2007 Survey/reported WHO/UNICEF
94 2006 Survey/reported WHO/UNICEF
93 2005 Survey/reported WHO/UNICEF
92 2004 Survey/reported WHO/UNICEF
92 2003 Survey/reported WHO/UNICEF
91 2002 Survey/reported WHO/UNICEF
90 2001 Survey/reported WHO/UNICEF
89 2000 Survey/reported WHO/UNICEF
88 1999 Survey/reported WHO/UNICEF
69 1998 Survey/reported WHO/UNICEF
50 1997 Survey/reported WHO/UNICEF
12 1996 Survey/reported WHO/UNICEF
12 1995 Survey/reported WHO/UNICEF
2 1994 Survey/reported WHO/UNICEF
2 1993 Survey/reported WHO/UNICEF
15 1992 Survey/reported WHO/UNICEF
10 1991 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
76 2017 Survey/reported EMCDDA, 2019
53 (43 - 65) 2014 Survey/reported Reitox National Focal Point, 2014
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
65 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Source: WHO
Eligible for HBV generic medicines
Source: MPP
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
Source: MPP
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
NSP in at least one prison
No
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
Yes
Source: Harm Reduction International
OST in at least one prison
Yes
Source: Harm Reduction International
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
Source: WHO
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Source: WHO

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.61 (0.50 - 0.75) 2019 Modelled IHME
0.61 (0.50 - 0.74) 2018 Modelled IHME
0.6 (0.49 - 0.74) 2017 Modelled IHME
0.59 (0.49 - 0.73) 2016 Modelled IHME
0.58 (0.47 - 0.72) 2015 Modelled IHME
0.57 (0.47 - 0.71) 2014 Modelled IHME
0.57 (0.47 - 0.70) 2013 Modelled IHME
0.56 (0.46 - 0.69) 2012 Modelled IHME
0.56 (0.46 - 0.69) 2011 Modelled IHME
0.56 (0.46 - 0.68) 2010 Modelled IHME
0.55 (0.45 - 0.68) 2009 Modelled IHME
0.55 (0.45 - 0.68) 2008 Modelled IHME
0.55 (0.45 - 0.68) 2007 Modelled IHME
0.54 (0.44 - 0.68) 2006 Modelled IHME
0.54 (0.44 - 0.67) 2005 Modelled IHME
0.52 (0.43 - 0.64) 2004 Modelled IHME
0.48 (0.40 - 0.59) 2003 Modelled IHME
0.44 (0.36 - 0.54) 2002 Modelled IHME
0.41 (0.34 - 0.49) 2001 Modelled IHME
0.39 (0.32 - 0.48) 2000 Modelled IHME
0.39 (0.32 - 0.47) 1999 Modelled IHME
0.4 (0.33 - 0.47) 1998 Modelled IHME
0.4 (0.33 - 0.48) 1997 Modelled IHME
0.4 (0.33 - 0.48) 1996 Modelled IHME
0.41 (0.34 - 0.49) 1995 Modelled IHME
0.42 (0.35 - 0.50) 1994 Modelled IHME
0.45 (0.37 - 0.54) 1993 Modelled IHME
0.48 (0.40 - 0.58) 1992 Modelled IHME
0.53 (0.44 - 0.64) 1991 Modelled IHME
0.58 (0.47 - 0.71) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
2.2 (1.30 - 3.40) 2010 Survey/reported Drositis et al, 2013
1.9 (0.50 - 2.60) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
65.7 (61.80 - 69.50) 2014 Modelled Degenhardt L et al, 2017
68.1 (65.50 - 70.60) 2013 Survey/reported EMCDDA
Showing out of
Show more

HCV-related death rate

National
Download
Value (per 100,000) Year Type Source
3.84 (2.96 - 4.85) 2019 Modelled IHME
3.78 (2.95 - 4.73) 2018 Modelled IHME
3.67 (2.84 - 4.57) 2017 Modelled IHME
3.63 (2.81 - 4.53) 2016 Modelled IHME
3.55 (2.76 - 4.45) 2015 Modelled IHME
3.49 (2.70 - 4.37) 2014 Modelled IHME
3.46 (2.68 - 4.35) 2013 Modelled IHME
3.4 (2.64 - 4.33) 2012 Modelled IHME
3.27 (2.54 - 4.19) 2011 Modelled IHME
3.15 (2.45 - 4.01) 2010 Modelled IHME
3.09 (2.41 - 3.95) 2009 Modelled IHME
3 (2.33 - 3.84) 2008 Modelled IHME
2.94 (2.29 - 3.80) 2007 Modelled IHME
2.81 (2.18 - 3.65) 2006 Modelled IHME
2.78 (2.15 - 3.61) 2005 Modelled IHME
2.77 (2.14 - 3.58) 2004 Modelled IHME
2.79 (2.16 - 3.61) 2003 Modelled IHME
2.79 (2.17 - 3.62) 2002 Modelled IHME
2.83 (2.20 - 3.66) 2001 Modelled IHME
2.86 (2.22 - 3.70) 2000 Modelled IHME
2.9 (2.22 - 3.75) 1999 Modelled IHME
2.92 (2.23 - 3.77) 1998 Modelled IHME
2.95 (2.26 - 3.84) 1997 Modelled IHME
3.01 (2.28 - 3.93) 1996 Modelled IHME
3.06 (2.32 - 3.99) 1995 Modelled IHME
3.13 (2.35 - 4.08) 1994 Modelled IHME
3.21 (2.42 - 4.21) 1993 Modelled IHME
3.29 (2.48 - 4.31) 1992 Modelled IHME
3.27 (2.46 - 4.31) 1991 Modelled IHME
3.28 (2.47 - 4.31) 1990 Modelled IHME
Showing out of
Show more
Technical notes

HCV-related deaths

National
Download
Value Year Type Source
397 (306 - 502) 2019 Modelled IHME
393 (306 - 492) 2018 Modelled IHME
384 (297 - 478) 2017 Modelled IHME
382 (296 - 476) 2016 Modelled IHME
376 (292 - 472) 2015 Modelled IHME
373 (289 - 467) 2014 Modelled IHME
373 (289 - 470) 2013 Modelled IHME
371 (288 - 473) 2012 Modelled IHME
361 (280 - 462) 2011 Modelled IHME
349 (271 - 445) 2010 Modelled IHME
344 (267 - 439) 2009 Modelled IHME
334 (259 - 427) 2008 Modelled IHME
327 (255 - 423) 2007 Modelled IHME
314 (243 - 407) 2006 Modelled IHME
310 (240 - 403) 2005 Modelled IHME
309 (239 - 399) 2004 Modelled IHME
311 (241 - 402) 2003 Modelled IHME
312 (242 - 405) 2002 Modelled IHME
315 (245 - 408) 2001 Modelled IHME
317 (246 - 411) 2000 Modelled IHME
321 (246 - 414) 1999 Modelled IHME
321 (246 - 415) 1998 Modelled IHME
322 (247 - 420) 1997 Modelled IHME
327 (248 - 427) 1996 Modelled IHME
330 (251 - 431) 1995 Modelled IHME
336 (252 - 438) 1994 Modelled IHME
342 (257 - 448) 1993 Modelled IHME
347 (262 - 456) 1992 Modelled IHME
342 (258 - 451) 1991 Modelled IHME
341 (257 - 448) 1990 Modelled IHME
527 2016 Modelled WHO
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
21 (15 - 28) 2019 Modelled IHME
21 (15 - 28) 2018 Modelled IHME
21 (15 - 28) 2017 Modelled IHME
21 (14 - 28) 2016 Modelled IHME
20 (14 - 27) 2015 Modelled IHME
20 (14 - 27) 2014 Modelled IHME
20 (14 - 27) 2013 Modelled IHME
20 (14 - 27) 2012 Modelled IHME
20 (14 - 27) 2011 Modelled IHME
20 (14 - 27) 2010 Modelled IHME
20 (14 - 27) 2009 Modelled IHME
20 (14 - 27) 2008 Modelled IHME
20 (14 - 26) 2007 Modelled IHME
19 (14 - 26) 2006 Modelled IHME
19 (13 - 26) 2005 Modelled IHME
19 (14 - 25) 2004 Modelled IHME
19 (14 - 25) 2003 Modelled IHME
19 (13 - 25) 2002 Modelled IHME
19 (13 - 25) 2001 Modelled IHME
19 (13 - 25) 2000 Modelled IHME
19 (13 - 25) 1999 Modelled IHME
19 (14 - 25) 1998 Modelled IHME
19 (14 - 26) 1997 Modelled IHME
19 (14 - 26) 1996 Modelled IHME
19 (14 - 26) 1995 Modelled IHME
19 (14 - 26) 1994 Modelled IHME
19 (14 - 26) 1993 Modelled IHME
19 (14 - 26) 1992 Modelled IHME
20 (14 - 26) 1991 Modelled IHME
20 (14 - 27) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 2017 Survey/reported EMCDDA, 2019
53 (43 - 65) 2014 Survey/reported Reitox National Focal Point, 2014
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
65 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Source: WHO
Eligible for HBV generic medicines
Source: MPP
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
Source: MPP
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
NSP in at least one prison
No
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
Yes
Source: Harm Reduction International
OST in at least one prison
Yes
Source: Harm Reduction International
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
Source: WHO
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Source: WHO

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
1.8 (%)
2019
(1.65 - 1.97(%))
IHME
HCV (RNA/cAg+)
0.61 (%)
2019
(0.5 - 0.75(%))
IHME

Survey/surveillance

No data available
HCV (anti-HCV)
2.2 (%)
2010
(1.3 - 3.4(%))
Drositis et al, 2013

Hepatitis related deaths (national)

Modelled

HBV
372
2019
(299 - 463)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
397
2019
(306 - 502)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.05 (%)
2019, latest modelled
(0.04 - 0.07(%))
IHME

Prevalence PWID

HCV
68.10 (%)
2013, survey/surveillance
(65.50 - 70.60(%))
EMCDDA

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
76
2017
EMCDDA, 2019
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources